People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Immunologix, Inc. | — | Biotechnology | Seed | $1.5M | $11.1M | 2010 |
| Amalgent Therapeutics, LLC | — | Pharmaceuticals | Pre-Seed | $200K | $3.4M | 2022 |
Sam A Tetlow at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sam A Tetlow on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Lloyd A. Pearson | 1 | 3 |
| Douglas M. Carnes | 1 | 3 |
| Ryan N. Fiorini | 1 | 3 |
| Mark Bartosh | 1 | 2 |
| Malcolm A Meyn | 1 | 1 |
| Richard A. McGregor | 1 | 1 |
| Robert N. Kennedy | 1 | 1 |
| Robert A. Kennedy | 1 | 1 |
| Mark A. Bartosh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.